Open in interactive viewer → charts, metric popovers & call review

TG Therapeutics Has a Billion-Dollar Run Rate — and a Competitor Crying Foul

A quiet 2x in nine months, a raised guide to $1B, and a fight over whether BRIUMVI's share gains are built to last
TGTX · Earnings Call · 2026-11-09

The Billion Is Real; the Argument Is Over How It Was Won

TG Therapeutics just did something almost no biotech does: it turned a single launched drug into roughly a $1 billion annual business in under four years. Third-quarter 2026 total revenue came in near $260M, including $233M of U.S. BRIUMVI net product revenue (up 52% year-over-year), and management lifted its full-year global guide to approximately $1 billion while nudging U.S. BRIUMVI to $915M–$920M. The stock has already noticed — up about 14% over the last 90 days and, more strikingly, more than doubled over the trailing ~36 weeks. So the question on this call was no longer can they sell it. It was is the way they're selling it durable — and what is the second act.

From Story Stock to Cash Machine

The mechanics here are the real headline, and they're less flattering at first glance than the top line. Free-cash-flow discipline has arrived, with operating income stepping to $86M in the quarter versus $29M a year ago. Net income, by contrast, fell to $55.5M — but that is a mirage of comparability: last year's third quarter carried a large non-cash tax benefit from releasing a deferred-tax valuation allowance, which Sean Power flagged explicitly. Strip that out and the direction of travel is unmistakable. What's worth checking against the filings is that the 10-Q on record still reflects Q2 (revenue $240M, period ended early August), so the $260M quarter hasn't yet been papered into the formal financials. On the trailing numbers we do have, the revenue ramp is a genuine hockey stick, and the price-to-revenue multiple has compressed from nosebleed levels to something a grown-up company might recognize: roughly 10.5x sales, down about 16% year-over-year. That is the market paying less per dollar of revenue because the dollars are finally arriving. The guidance choreography tells its own story. On the August call, U.S. BRIUMVI guidance sat at $890M–$905M; now it's $915M–$920M, and the full company crosses $1B globally. CFO Sean Power framed the quarter plainly: “Overall, it was another strong quarter financially. We delivered significant revenue growth, generated meaningful profitability, and continued investing in the business while returning capital to shareholders.” — Sean Power, Chief Financial Officer · 2026-11-09 Analysts kept pressing on the new-versus-switch mix and the shape of the quarterly trajectory — the recurring growth dynamics question — and management's answer, that there are simply more patients entering the franchise than leaving it, is the one that matters.

"Clearly, We're Having an Impact"

The sharpest moment came from Evercore: a competitor had told its own investors that BRIUMVI was winning share through aggressive contracting that "is probably not sustainable." Adam Waldman did not retreat.

I think it's great that the competitor is talking about us on their calls. Clearly, we're having an impact on their business. But to be clear, our contracting approach is both competitive and we believe 100% sustainable.

Adam Waldman, Chief Commercial Officer · 2026-11-09
That is a real tension to hold in view. Gross-to-net has been a running character in this story for over a year — Adam noted in February 2026 that “gross to net can vary quarter-to-quarter” — Adam Waldman, Chief Commercial Officer · 2026-02-26, and reaffirmed a roughly 65% average for the year. A competitor publicly questioning the durability of your discounting, while you answer that price increases offset the pressure, is exactly the kind of thing that deserves a skeptical eye. A genuinely new wrinkle this quarter was the 340B policy question, which management defused by noting government-exposed Medicare-at-340B business is only about 5% of revenue — small enough to look like a manageable, not existential, overhang. The competitive backdrop helps TG's case: the BTK class was again dismissed as an oral-market competitor rather than a CD20 threat after its ECTRIMS readouts underwhelmed, with remibrutinib's efficacy described as falling short on relapse and MRI endpoints. TG has made this point for several quarters now, and the data has kept agreeing with them.

The 2028 Promise and the Immune-Reset Moonshot

What the company is really asking investors to underwrite is the second act. The subcutaneous self-administered BRIUMVI is fully enrolled, with Phase III data due around year-end or early 2027 and a potential 2028 launch. Adam's pitch hasn't changed in spirit but keeps escalating in size: “we believe the addition of subcu can more than double BRIUMVI peak sales opportunity by opening an entirely new segment of the anti-CD20 market where we don't currently participate.” — Adam Waldman, Chief Commercial Officer · 2026-11-09 This is a phrase fans of the story have heard before — Mike called subcu an "order of magnitude change" on the August call — and the self administration segment, roughly 35% of new anti-CD20 starts, is the untapped pool everyone is chasing. The genuinely fresh science was azer-cel, the allogeneic CAR-T, where TG presented its first clinical data in progressive MS — 26 patients, no dose-limiting toxicities, and peripheral B cell depletion in 25 of 26. The CAR T cell therapy angle matters commercially because the broader immune-reset trade is live across biotech right now: B-cell-malignancy names like B cell malignancies plays were among the stronger movers in the recent tape, and multiple reporters this week leaned on late-stage autoimmune and oncology pipelines. TG is riding a wave, but it is not inventing the wave.
What it also is not doing is abandoning the anti CD20 therapy cash cow to fund the science. Management was emphatic that subcu is additive, not a swap — "two substantial businesses under one brand" — backed by patents into the mid-2040s.

What the Tape and the Balance Sheet Whisper

The stock has run hard, and the hospital channel is the quiet reason the fourth quarter looks strong: “September and October being our strongest hospital months since launch” — Adam Waldman, Chief Commercial Officer · 2026-11-09 is the kind of statement that precedes an upgrade cycle, not follows one. Yet there is a tension worth naming. TG repurchased $100M of stock in Q3 at roughly $49 a share — well above the sub-$34 average across its $300M of cumulative buybacks. Buying back your own shares above your historical cost is a confident bet, or a late one, depending on your view of 2028. More quietly, the balance sheet is not as gun-slung as the $557M cash headline suggests. On an effective-net-cash basis — gross cash less total debt — the company actually sits at about negative $192M, a swing of roughly $200M over the past year, plausibly tied to the royalty-style credit facility that has funded the buyback-and-invest posture. That is not alarming for a company generating operating income — but it reframes the capital-allocation swagger.

The Bottom Line

TG Therapeutics has crossed from "promising platform" to "profitable franchise" without the market fully repricing what that means. The revenue is real, the guidance keeps rising, and the pipeline optionality — subcu in 2028, azer-cel in progressive MS — is the reason the multiple isn't a value-stock multiple. The competitive accusation over contracting is the one loose thread: if gross-to-net holds near 65% and price increases keep carrying the offset, Adam's "100% sustainable" line ages well. If it doesn't, the whole growth-dynamics story gets re-underwritten. For now, the cash machine and the moonshot are pointing the same direction — up.